MK-9470

MK-9470.svg

MK-9470 is a radioligand used in positron emission tomography (PET) imaging to study the cannabinoid receptor type 1 (CB1R) in the human brain. It is a synthetic compound developed by Merck & Co. for research purposes.

Chemical Properties

MK-9470 is a selective CB1R antagonist, which means it binds specifically to the CB1 receptors in the brain, blocking the action of endogenous cannabinoids. This property makes it useful for mapping the distribution and density of CB1 receptors in various regions of the brain.

Mechanism of Action

As a CB1R antagonist, MK-9470 competes with endogenous cannabinoids like anandamide and 2-arachidonoylglycerol (2-AG) for binding to the CB1 receptors. By doing so, it inhibits the normal action of these endogenous ligands, allowing researchers to study the role of CB1 receptors in various physiological and pathological processes.

Applications in Research

MK-9470 has been used extensively in neuroscience research to investigate the role of the endocannabinoid system in various conditions, including neurodegenerative diseases, psychiatric disorders, and substance abuse. PET imaging with MK-9470 allows for the visualization and quantification of CB1 receptor distribution in the living brain, providing valuable insights into the functioning of the endocannabinoid system.

Safety and Efficacy

As a research compound, MK-9470 is not intended for therapeutic use in humans. Its safety and efficacy have been evaluated in preclinical studies and clinical trials primarily to understand its binding characteristics and potential as a diagnostic tool.

Related Compounds

Other radioligands used for imaging CB1 receptors include AM251, SR141716A (Rimonabant), and CP-55940. These compounds vary in their selectivity and affinity for CB1 receptors, offering different advantages and limitations for research purposes.

See Also

• Cannabinoid receptor
• Endocannabinoid system
• Positron emission tomography
• Neuroimaging
• Radioligand